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9 with IgE sensitization in young children
10
11 To the Editor, 
12 The prevalence of immune-mediated diseases is continuously rising.1,2 In addition to genetic 
13 predisposition, socioeconomic circumstances and environmental factors may modulate the development 
14 of these diseases. Although the mechanisms leading to abnormal immune responses in autoimmune and 
15 allergic diseases may share some common pathways, the detailed pathogenesis of these conditions are 
16 still inadequately understood. The results on co-existence of allergic and autoimmune diseases have been 
17 hitherto inconsistent, some indicating co-existence3,4 and others the opposite or no relationship at all.5,6
18 The aim of the current study was to examine the relationship between allergen-specific IgE (sIgE) 
19 sensitization patterns, human leukocyte antigen (HLA)-conferred disease susceptibility, and 
20 autoimmunity-associated outcomes in Finland, Estonia, and Russian Karelia. These three geographically 
21 adjacent areas represent socioeconomically diverse countries with only modest differences in frequencies 
22 of HLA haplotypes conferring risk for type 1 diabetes (T1D) and coeliac disease (CD),7 but they differ 
23 remarkably in the prevalence of immune-mediated diseases.8
24 Children born in Finland, Estonia, and Russian Karelia were observed prospectively either from birth 
25 up to the age of 3 or from 3 to 5 years of age. Children in the birth cohort (BC; n=714) carried HLA-
26 conferred susceptibility to T1D and CD; either a combination of DR3-DQ2 and DR4-DQ8 haplotypes or 
27 alternatively DR4-DQ8/X (X=DR4-DQ8 or a neutral haplotype) or DR3-DQ2/Y (Y=DR3-DQ2 or a neutral 
28 haplotype) genotypes. Children in the young children’s cohort (YCC; n=3580) represented the general 
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29 population, with no selection based on HLA genotype. The participants were monitored for the 
30 appearance of sIgEs (≥0.35 kU/l) against dietary (egg, milk, peanut) and aeroallergens (cat, dog, dust mite, 
31 birch, timothy), signs of T1D-associated islet autoimmunity (IA) or CD-associated tissue transglutaminase 
32 antibody (tTGA) positivity and progression to clinical T1D or CD. Detailed methodology is provided in the 
33 Supporting Information.
34 A total of 37.5% of children in the BC and 39.4% in the YCC had been sensitised to at least one 
35 specific allergen during the respective follow-up (Table S1). Both cohorts showed similar proportions of 
36 dietary allergen sensitisations (88.1% vs. 83.3% of the sensitised), but sensitised children in the BC were 
37 less often sensitised to aeroallergens (41.0% vs. 63.6%, P<0.001) and to both dietary and aeroallergens 
38 (29.1% vs. 46.9%, P<0.001). Finnish children developed allergen-specific sensitisation most frequently, 
39 followed by Estonian and Russian Karelian participants (Table 1). Sensitisation rates were higher among 
40 males than among females in both cohorts (P<0.02). The distributions of HLA risk groups did not differ 
41 between sensitised and non-sensitised children in either cohort. 
42 At the age of 3 years, 38.5% of the BC children and 30.2% of the YCC children had at least one 
43 positive sIgE (P<0.001; Figure 1A). This difference was seen especially in Estonians (34.2% vs. 27.2%, 
44 P=0.035) and weakly in Finns (41.2% vs. 35.1%, P=0.057). A similar difference was observed for dietary 
45 allergen sensitisation at the age of 3 years (31.7% vs. 24.1% in BC and YCC respectively, P<0.001; Figure 
46 1B), being also present in Finns (34.7% vs. 28.7%, P=0.046) but not clearly so in Estonians (27.1% vs. 
47 21.3%, P=0.061). Aeroallergen sensitisation at 3 years was more frequent in the BC children than in the 
48 YCC children (18.7% vs. 13.1%, P=0.001; Figure 1C; in Finland 20.4% vs. 15.5%, P=0.045; in Estonia 16.4% 
49 vs. 11.6%, P=0.048). 
50 When combining both cohorts, at the age of 3 years males were more frequently sensitised to at 
51 least one specific allergen compared to females (33.1% vs. 29.2%, P=0.009; dietary allergens 25.8% vs. 
52 24.3%, P=0.288; aeroallergens 14.8% vs. 12.7%, P=0.053). Children with HLA risk genotypes for T1D and 
53 CD were more frequently sensitised compared to children with HLA risk groups associated with neutral or 
54 protective effect on the disease risk (34.2% vs. 30.3%, P=0.016); also seen in sensitisation to dietary 
55 allergens (27.8% vs. 24.3%, P=0.025), but not in sensitisation to aeroallergens (15.2% vs. 13.3%, P=0.125).
56 Sensitised children in both the BC and the YCC had higher odds to test positive for tTGA during their 
57 respective follow-up, compared to non-sensitised children (Table 1). In the YCC, sensitised children had 
58 also over six times the odds to be diagnosed with CD during the follow-up. 
59 In contrast to other studies that have reported co-occurrence of atopic sensitization and T1D,3,4 we 
60 did not observe any correlation between sIgE sensitisation and T1D or IA. In the current study, sensitised 
61 children did, however, have higher risk for CD and tTGA positivity in contrast to a Swedish study that A
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62 reported no co-existence between self-reported allergies and CD.6 As sIgE sensitisation at the age of 3 
63 years was more frequent in children with HLA-conferred risk genotypes compared to children without 
64 these risk genotypes as well as compared to the general population, these results demonstrate that 
65 atopic and autoimmune diseases can be co-occurring. Our results support the idea of a common 
66 denominator in allergic and autoimmune diseases that may be especially crucial in early childhood, when 
67 the immune system is not yet fully mature. Since sIgE sensitisation was associated with HLA-conferred 
68 susceptibility to T1D and CD, but clinically only to CD and its associated autoimmunity, one might 
69 speculate that the pathomechanisms of atopic sensitisation share more common pathways with CD than 
70 with T1D.
71 The prospective study setting, with the interesting pools of children genetically at-risk vs. the 
72 general population allowed us to compare these two cohorts at the age of 3 years. One has to keep in 
73 mind that sIgE alone does not indicate clinical allergy, but together with positive skin prick tests and 
74 consistent allergy symptoms, they form a more accurate risk profile for future allergies. Poor study 
75 compliance in Russian Karelia in both cohorts were unfortunate and did not allow us to perform proper 
76 analyses between all three countries at all ages. 
77 To conclude, we found that children carrying HLA genes predisposing to T1D and CD are more 
78 frequently sIgE sensitised at 3 years of age. We also observed that sensitisation to common allergens 
79 increases the risk of positivity for tTGA and for CD, but not for IA or T1D. The contemporaneous 
80 occurrence of atopic markers and autoimmune diseases suggests that these diseases may share some 
81 common pathogenic features.
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
82 References
83 1. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, 
84 allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-
85 sectional surveys. Lancet. 2006;368:733–743. 
86 2. Patterson CC, Gyürüs E, Rosenbauer J, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-
87 2008: evidence of non-uniformity over time in rates of increase. Diabetologia. 2012;55:2142–2147.
88 3. Seiskari T, Viskari H, Kondrashova A, et al. Co-occurrence of allergic sensitization and type 1 diabetes. Ann Med. 
89 2010;42:352–359. 
90 4. Sheikh A, Smeeth L, Hubbard R. There is no evidence of an inverse relationship between TH2-mediated atopy and 
91 TH1-mediated autoimmune disorders: Lack of support for the hygiene hypothesis. J Allergy Clin Immunol. 
92 2003;111:131–135. 
93 5. Cardwell CR, Shields MD, Carson DJ, Patterson CC. A meta-analysis of the association between childhood type 1 
94 diabetes and atopic disease. Diabetes Care. 2003;26:2568–2574. 
95 6. Enroth S, Dahlbom I, Hansson T, Johansson Å, Gyllensten U. Prevalence and sensitization of atopic allergy and 
96 coeliac disease in the Northern Sweden Population Health Study. Int J Circumpolar Health. 2013;72:21403. 
97 7. Nejentsev S, Koskinen S, Sjöroos M, et al. Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA 
98 alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Tissue 
99 Antigens. 1998;52:473–477
100 8. Kondrashova A, Seiskari T, Ilonen J, Knip M, Hyöty H. The "hygiene hypothesis" and the sharp gradient in the 
101 incidence of autoimmune and allergic diseases between Russian Karelia and Finland. APMIS 2013;121:478-493.
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
102 Authors and affiliations
103 Neea Mustonen1,2, Heli Siljander1,2, Aleksandr Peet3, Vallo Tillmann3, Taina Härkönen1,2, Onni Niemelä4, 
104 Raivo Uibo5, Jorma Ilonen6,7, Mikael Knip1,2,8,9, the DIABIMMUNE Study Group
105 1Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, 
106 Helsinki, Finland
107 2Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 
108 Helsinki, Finland
109 3Children’s Clinic of Tartu University Hospital and Institute of Clinical Medicine, University of Tartu, Tartu, 
110 Estonia
111 4Department of Laboratory Medicine and Medical Research Unit, Seinäjoki Central Hospital and University 
112 of Tampere, Seinäjoki, Finland 
113 5Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, 
114 Tartu, Estonia
115 6Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
116 7Clinical Microbiology, Turku University Hospital, Turku, Finland
117 8Folkhälsan Research Center, Helsinki, Finland
118 9Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland
119
120 Corresponding author
121 Mikael Knip, MD, PhD
122 Professor of Pediatrics
123 Children’s Hospital
124 University of Helsinki
125 P.O. Box 22, FI-00014 Helsinki, Finland
126 Phone: +358 50 448 7722
127 E-mail: mikael.knip@helsinki.fi 
128
129 Acknowledgements
130 The authors thank all the participating children and families in the DIABIMMUNE study as well as the 
131 physicians, nurses, and technicians in the DIABIMMUNE study centres and laboratories. 
132
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
133 Funding
134 The work was supported by the European Union Seventh Framework Programme (grant no. 202063), the 
135 Academy of Finland (Decision No. 292538, and Centre of Excellence in Molecular Systems Immunology 
136 and Physiology Research, Decision No. 250114), the Liv och Hälsa Fund, the Estonian Research Council 
137 (grants PUT1382 and IUT20-43), Finska Läkaresällskapet, Paulon Säätiö, Biomedicum Helsinki Foundation, 
138 and Suomen Lääketieteen Säätiö.
139
140 Conflict of Interest
141 The authors declare no conflict of interest.
142
143 Key words: aeroallergens, allergen-specific IgE, coeliac disease, dietary allergens, HLA
144
145 Word count: text 998
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
TABLE 1 Demographic and clinical characteristics of IgE sensitized and non-sensitized children. Values are medians and interquartile ranges if not 
otherwise indicated. 
Birth cohort Young children’s cohort
sIgE sensitized
n=268
Non-sensitized
n=446
P
sIgE sensitized
n=1412
Non-sensitized
n=2168
P
Proportion of males (%) 57.8 48.2 0.016 54.5 50.2 0.015
Country (%) <0.001 <0.001
Finland 45.6 54.4 46.0 54.0
Estonia 32.4 67.6 36.9 63.1
Russian Karelia 15.9 84.1 21.7 78.3
Maternal age at birth, years 30.6 (27.133.8) 29.9 (25.933.7) 0.087 30.6 (26.833.9) 30.1 (25.734.0) 0.021
Number of siblings at birth 0 (01) 1 (01) 0.231 0 (01) 1 (01) 0.070
Gestational age, weeks 40.1 (39.341.0) 40.1 (39.141.0) 0.939 40.0 (39.040.9) 40.0 (39.040.7) 0.004
Caesarean section (%) 8.6 11.0 0.366 21.0 19.7 0.346
Birth weight, g 3610 (32303910) 3589 (32733889) 0.768 3560 (32303930) 3534 (32003890) 0.116
Birth length, cm 51 (4952) 51 (5052) 0.778 51 (4952) 51 (4952) 0.665
HLA risk group (%) 0.783 0.543
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DR3-DQ2 / DR4-DQ8 10.1 8.5 1.9 1.4
DR4-DQ8 / X a 33.6 34.1 6.3 7.0
DR3-DQ2 / Y b 56.3 57.4 11.2 10.9
non-risk genotypes   80.6 80.7
Clinical outcomes [% (n)]
Islet autoimmunity c 6.7 (18) 6.1 (27) 0.846 6.2 (88) 4.7 (102) 0.055
Type 1 diabetes 1.5 (4) 1.6 (7) 1.000 0.5 (7) 0.5 (11) 1.000
Positivity for tTGA 3.7 (10) 0.7 (3) 0.008 d 1.8 (25) 0.7 (16) 0.007 e
Coeliac disease 2.2 (6) 0.7 (3) 0.142 1.1 (16) 0.2 (4) <0.001 f
a X=DR4-DQ8 or a neutral haplotype; b Y=DR3-DQ2 or a neutral haplotype; c positivity for insulin autoantibodies or antibodies to glutamic acid decarboxylase, islet 
antigen 2, or zinc transporter 8; d OR 5.7 (95CI 1.621.0); e OR 2.4 (95CI 1.34.6); f OR 6.2 (95CI 2.118.6)
sIgE, allergen-specific immunoglobulin E; HLA, human leukocyte antigen; tTGA, tissue transglutaminase antibody; OR, odds ratio; 95CI, 95% confidence interval
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1 Figure legend
2 FIGURE 1 Proportion of children with allergen-specific IgE in the birth cohort (BC) at 6, 18, and 36 months 
3 and in the young children’s cohort (YCC) at 3 and 5 years of age. At 3 years of age, children in the BC, who 
4 all carried HLA-conferred risk to type 1 diabetes and coeliac disease, were more frequently sensitized to 
5 A) any allergen (P<0.001), B) dietary allergen (P<0.001), and C) aeroallergen (P=0.001) compared to 
6 children in the YCC who represented the general population. In both cohorts, sensitization rates increased 
7 by age, with the exception of dietary allergen sensitization between 3 and 5 years of age in the YCC.
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